トシリズマブ（遺伝子組換え）［トシリズマブ後続１］ shortage — JP supply status & alternatives

トシリズマブ（遺伝子組換え）［トシリズマブ後続１］

—

In supply · Australia

トシリズマブＢＳ点滴静注２００ｍｇ「ＣＴ」

In supply · 🇦🇺 Australia · short in🇯🇵 JP

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	トシリズマブ（遺伝子組換え）［トシリズマブ後続１］
Brand names	トシリズマブＢＳ点滴静注２００ｍｇ「ＣＴ」
Therapeutic category	Auto-created by Ministry of Health, Labour and Welfare — Drug Supply Status scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇯🇵

Japan

PMDA · 10d ago

Medium

Verified timeline regulator events

🇯🇵 20 June 2026

medium reported

Sources official regulators

🇯🇵

PMDA

verified 10d ago

verify ↗

Mederti Drug Report

Generated 1 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.